Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding

Hye-Rim Kang; Bobby L Jones; Wei-Hsuan Lo-Ciganic; Christina E DeRemer; Eric A Dietrich; Pei-Lin Huang; Haesuk Park

doi:10.1016/j.rpth.2023.100131

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding

Res Pract Thromb Haemost. 2023 Mar 27;7(3):100131. doi: 10.1016/j.rpth.2023.100131. eCollection 2023 Mar.

Authors

Hye-Rim Kang¹, Bobby L Jones¹, Wei-Hsuan Lo-Ciganic^{1

2}, Christina E DeRemer³, Eric A Dietrich³, Pei-Lin Huang¹, Haesuk Park^{1

2}

Affiliations

¹ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
² Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
³ Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

Abstract

Background: Little is published about warfarin therapy adherence patterns beyond 6 months of initial anticoagulant treatment and their association with effectiveness and safety for patients with venous thromboembolism (VTE).

Objectives: To compare the risks of recurrent VTE and major bleeding during extended treatment between adherence patterns using MarketScan Commercial and Medicare Supplemental databases (2013-2019).

Methods: In a retrospective cohort study, we included patients with incident VTE who completed an initial 6-month anticoagulant treatment and received either warfarin or no extended therapy. Group-based trajectory models were used to identify distinct extended treatment trajectories. Associations between the trajectories and risk of hospitalization due to recurrent VTE and major bleeding were assessed using inverse probability treatment-weighted Cox proportional hazards models.

Results: Compared with no extended treatment, consistently high warfarin adherence was associated with a significantly decreased risk of hospitalization due to recurrent VTE (hazard ratio [HR] = 0.23; 95% CI, 0.12-0.45), but gradually (HR = 0.29; 95CI, 0.08-1.06) or rapidly declining (HR = 0.14; 95% CI, 0.02-1.24) adherence showed no association with the risk of hospitalization due to recurrent VTE. Compared with no extended treatment, warfarin extended therapy was associated with an increased risk of hospitalization due to major bleeding regardless of adherence patterns (consistently high: HR = 2.08; 95% CI, 1.18-3.64, gradually declining: HR = 2.10; 95% CI, 0.74-5.95, and rapidly declining: HR = 9.19; 95% CI, 4.38-19.29). However, compared with rapidly declining adherence, consistently high (HR = 0.23; 95% CI, 0.11-0.47) and gradually declining (HR = 0.23; 95% CI, 0.08-0.64) adherence were associated with decreased risk of hospitalization due to major bleeding.

Conclusion: The findings indicated that consistently high adherence to extended warfarin treatment was associated with a decreased risk of hospitalization due to recurrent VTE but an increased risk of hospitalization due to major bleeding compared with no extended treatment.

Keywords: bleeding; medication adherence; venous thromboembolism; warfarin.